JP2003526362A5 - - Google Patents

Download PDF

Info

Publication number
JP2003526362A5
JP2003526362A5 JP2001567304A JP2001567304A JP2003526362A5 JP 2003526362 A5 JP2003526362 A5 JP 2003526362A5 JP 2001567304 A JP2001567304 A JP 2001567304A JP 2001567304 A JP2001567304 A JP 2001567304A JP 2003526362 A5 JP2003526362 A5 JP 2003526362A5
Authority
JP
Japan
Prior art keywords
mva
cell line
cells
grow
vaccinia virus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2001567304A
Other languages
English (en)
Japanese (ja)
Other versions
JP2003526362A (ja
JP4759201B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2001/002703 external-priority patent/WO2001068820A1/en
Publication of JP2003526362A publication Critical patent/JP2003526362A/ja
Publication of JP2003526362A5 publication Critical patent/JP2003526362A5/ja
Application granted granted Critical
Publication of JP4759201B2 publication Critical patent/JP4759201B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2001567304A 2000-03-14 2001-03-10 変異ワクシニアウイルスアンカラ（ｍｖａ）の改変株 Expired - Fee Related JP4759201B2 (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DKPA200000410 2000-03-14
DKPA200000410 2000-03-14
DK200000410 2000-03-14
PCT/EP2001/002703 WO2001068820A1 (en) 2000-03-14 2001-03-10 Altered strain of the modified vaccinia virus ankara (mva)

Publications (3)

Publication Number Publication Date
JP2003526362A JP2003526362A (ja) 2003-09-09
JP2003526362A5 true JP2003526362A5 (enExample) 2011-01-27
JP4759201B2 JP4759201B2 (ja) 2011-08-31

Family

ID=8159327

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2001567304A Expired - Fee Related JP4759201B2 (ja) 2000-03-14 2001-03-10 変異ワクシニアウイルスアンカラ（ｍｖａ）の改変株

Country Status (25)

Country Link
US (1) US6682743B2 (enExample)
EP (1) EP1263936B1 (enExample)
JP (1) JP4759201B2 (enExample)
KR (1) KR100880765B1 (enExample)
CN (1) CN1291012C (enExample)
AT (1) ATE305030T1 (enExample)
AU (1) AU780696B2 (enExample)
BR (1) BR0109158A (enExample)
CA (1) CA2397675C (enExample)
CZ (1) CZ293690B6 (enExample)
DE (1) DE60113512T2 (enExample)
DK (1) DK1263936T3 (enExample)
EE (1) EE05633B1 (enExample)
ES (1) ES2249430T3 (enExample)
HK (1) HK1052725B (enExample)
HU (1) HU228691B1 (enExample)
IL (3) IL150736A0 (enExample)
MX (1) MXPA02008873A (enExample)
NO (1) NO20024246D0 (enExample)
NZ (1) NZ521270A (enExample)
PL (1) PL205922B1 (enExample)
RU (1) RU2280075C2 (enExample)
SI (1) SI1263936T1 (enExample)
UA (1) UA84388C2 (enExample)
WO (1) WO2001068820A1 (enExample)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7628980B2 (en) 2000-11-23 2009-12-08 Bavarian Nordic A/S Modified vaccinia virus ankara for the vaccination of neonates
DE20122302U1 (de) 2000-11-23 2005-02-24 Bavarian Nordic A/S Variante des Modifizierten Vaccinia-Ankara-Virus
US7097842B2 (en) 2000-11-23 2006-08-29 Bavarian Nordic A/S Modified vaccinia virus ankara for the vaccination of neonates
US7445924B2 (en) * 2000-11-23 2008-11-04 Bavarian Nordic A/S Modified Vaccinia Ankara virus variant and cultivation method
EP1357127A1 (de) * 2002-04-10 2003-10-29 Immusystems GmbH CD4+ T-Lymphozyten spezifische Hepatitis C Virus-Epitope
JP4801880B2 (ja) † 2002-04-19 2011-10-26 バヴァリアン・ノルディック・アクティーゼルスカブ 新生仔予防接種用変異ワクシニアウイルスアンカラ
EP2253709B1 (en) * 2002-05-16 2018-04-11 Bavarian Nordic A/S Recombinant poxvirus expressing homologous genes inserted into the poxviral genome
US7501127B2 (en) 2002-05-16 2009-03-10 Bavarian Nordic A/S Intergenic regions as novel sites for insertion of HIV DNA sequences in the genome of Modified Vaccinia virus Ankara
UA85543C2 (ru) * 2002-09-05 2009-02-10 Бавариан Нордик А/С Способ культивирования первичных клеток и амплификации вирусов в условиях безсывороточной среды, композиция и ее применение, и способ лечения или вакцинации животных
WO2005048957A2 (en) 2003-02-20 2005-06-02 Therion Biologics Corporation Novel insertion sites in pox vectors
EP1518932A1 (en) * 2003-09-29 2005-03-30 GSF-Forschungszentrum für Umwelt und Gesundheit GmbH Modified vaccinia virus Ankara (MVA) mutant and use thereof
US7423155B2 (en) 2003-11-14 2008-09-09 3M Innovative Properties Company N-sulfonyldicarboximide containing tethering compounds
DE602004009743T2 (de) * 2003-11-24 2008-08-28 Bavarian Nordic A/S Promotoren zur Expression in modifiziertem Vaccinia Virus Ankara
DE102004003572A1 (de) * 2004-01-23 2005-08-18 Bavarian Nordic A/S Monoparamunitätsinducer basierend auf attenuierten Myxomaviren des Kaninchens
US20090269365A1 (en) * 2005-04-20 2009-10-29 University Of Washington Immunogenic vaccinia peptides and methods of using same
EP1835031A1 (en) 2006-03-14 2007-09-19 Paul-Ehrlich-Institut Bundesamt für Sera und Impfstoffe Use of a recombinant modified vaccinia virus Ankara (MVA) for the treatment of type I hypersensitivity in a living animal including humans
US7607323B1 (en) 2007-10-16 2009-10-27 Hall Charles F Curl resistant shirt collar and method of fabricating same
US8691502B2 (en) 2008-10-31 2014-04-08 Tremrx, Inc. T-cell vaccination with viral vectors via mechanical epidermal disruption
WO2011063359A1 (en) * 2009-11-20 2011-05-26 Inviragen, Inc. Compositions, methods and uses for poxvirus elements in vaccine constructs
US9005632B2 (en) 2009-11-20 2015-04-14 Takeda Vaccines, Inc. Compositions, methods and uses for poxvirus elements in vaccine constructs against influenza virus subtypes or strains
WO2011087839A1 (en) 2009-12-22 2011-07-21 Baxter International Inc. Vaccine to influenza a virus
WO2012151272A2 (en) 2011-05-02 2012-11-08 Tremrx, Inc. T-cell vaccination with viral vectors via mechanical epidermal disruption
DE102013004595A1 (de) 2013-03-15 2014-09-18 Emergent Product Development Germany Gmbh RSV-Impfstoffe
WO2015077717A1 (en) 2013-11-25 2015-05-28 The Broad Institute Inc. Compositions and methods for diagnosing, evaluating and treating cancer by means of the dna methylation status
US11725237B2 (en) 2013-12-05 2023-08-15 The Broad Institute Inc. Polymorphic gene typing and somatic change detection using sequencing data
EP3082853A2 (en) 2013-12-20 2016-10-26 The Broad Institute, Inc. Combination therapy with neoantigen vaccine
US20170021009A1 (en) * 2014-03-10 2017-01-26 Arizona Board Of Regents On Behalf Of Arizona State Heat Inactivated Poxvirus Improves Vaccination Results
WO2016100975A1 (en) 2014-12-19 2016-06-23 Massachsetts Institute Ot Technology Molecular biomarkers for cancer immunotherapy
WO2016100977A1 (en) 2014-12-19 2016-06-23 The Broad Institute Inc. Methods for profiling the t-cel- receptor repertoire
NL2014148B1 (en) 2015-01-16 2017-01-05 Univ Erasmus Med Ct Rotterdam Combination vaccine for camelids.
WO2016144564A2 (en) * 2015-02-25 2016-09-15 Memorial Sloan-Kettering Cancer Center Use of inactivated nonreplicating modified vaccinia virus ankara (mva)as monoimmunotherapy or in combination with immune checkpoint blocking agents for solid tumors
CR20200476A (es) 2015-05-20 2020-12-02 Dana Farber Cancer Inst Inc ANTÍGENOS COMPARTIDOS (Divisional 2017-0584)
TW202241500A (zh) 2015-06-09 2022-11-01 美商博德研究所有限公司 用於贅瘤疫苗之調配物及其製備方法
FR3042121A1 (fr) 2015-10-08 2017-04-14 Jean-Marc Limacher Composition anti-tumorale
EP3446119A1 (en) 2016-04-18 2019-02-27 The Broad Institute Inc. Improved hla epitope prediction
WO2018140391A1 (en) 2017-01-24 2018-08-02 The Broad Institute, Inc. Compositions and methods for detecting a mutant variant of a polynucleotide
US11306292B2 (en) 2017-05-15 2022-04-19 Janssen Vaccines & Prevention B.V. Stable virus-containing composition
JP7406377B2 (ja) 2017-05-15 2023-12-27 ヤンセン ファッシンズ アンド プリベンション ベーフェー 安定なウイルス含有組成物
JP7551496B2 (ja) 2017-10-31 2024-09-17 カリヴィル イムノセラピューティクス， インコーポレイテッド 全身送達のためのプラットフォーム腫瘍溶解性ベクター
CN111315407B (zh) 2018-09-11 2023-05-02 上海市公共卫生临床中心 一种广谱抗流感疫苗免疫原及其应用
US20210382068A1 (en) 2018-10-02 2021-12-09 Dana-Farber Cancer Institute, Inc. Hla single allele lines
US20220062394A1 (en) 2018-12-17 2022-03-03 The Broad Institute, Inc. Methods for identifying neoantigens
US12394502B2 (en) 2019-10-02 2025-08-19 The General Hospital Corporation Method for predicting HLA-binding peptides using protein structural features
WO2022232375A1 (en) 2021-04-30 2022-11-03 Kalivir Immunotherapeutics, Inc. Oncolytic viruses for modified mhc expression
WO2023077147A2 (en) 2021-11-01 2023-05-04 Pellis Therapeutics, Inc. T-cell vaccines for patients with reduced humoral immunity
US20250361513A1 (en) * 2022-05-04 2025-11-27 University Of Maryland, College Park Rna vectors with hairpin-like inserts
US20230364227A1 (en) 2022-05-12 2023-11-16 Pellis Therapeutics, Inc. Poxvirus adjuvant for t-cell vaccination
WO2024015892A1 (en) 2022-07-13 2024-01-18 The Broad Institute, Inc. Hla-ii immunopeptidome methods and systems for antigen discovery
FR3160186A1 (fr) 2024-03-13 2025-09-19 Odimma Therapeutics Vecteur non-viral pour transcription augmentee

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1341245C (en) * 1988-01-12 2001-06-05 F. Hoffmann-La Roche Ag Recombinant vaccinia virus mva
DE4405841C1 (de) * 1994-02-23 1995-01-05 Mayr Anton Prof Dr Med Vet Dr Multipotente Paramunitätsinducer auf der Basis von Kombinationen von Pockenviruskomponenten, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
RU2076735C1 (ru) * 1994-03-23 1997-04-10 ГНЦВБ "Вектор" Живая рекомбинантная вакцина гепатита в на основе вируса осповакцины для перорального применения и способ ее получения
UA68327C2 (en) 1995-07-04 2004-08-16 Gsf Forschungszentrum Fur Unwe A recombinant mva virus, an isolated eukaryotic cell, infected with recombinant mva virus, a method for production in vitro of polypeptides with use of said cell, a method for production in vitro of virus parts (variants), vaccine containing the recombinant mva virus, a method for immunization of animals
JP4460762B2 (ja) * 1997-10-15 2010-05-12 旭化成ファーマ株式会社 トロンボモジュリン水溶液注射剤の貯蔵・流通時の品質保持方法
JP3736622B2 (ja) * 2001-06-15 2006-01-18 セイコーエプソン株式会社 ライン駆動回路、電気光学装置及び表示装置

Similar Documents

Publication Publication Date Title
JP2003526362A5 (enExample)
CN100335619C (zh) 大规模生产病毒抗原的方法
PT1434858E (pt) Método de amplificação de um poxvírus em condições sem soro
JP2005532779A5 (enExample)
Kim et al. Whole-genome sequencing and genetic characteristics of representative porcine reproductive and respiratory syndrome virus (PRRSV) isolates in Korea
IL163701A0 (en) Modified vaccinia virus ankara for the vaccinationof neonates
RU2011148791A (ru) Иммортализованные линии клеток птиц и их применение
KR100908377B1 (ko) 바이러스 증식 방법
CN107190022A (zh) 一种快速构建禽传染性支气管炎病毒反向遗传株的方法
CN107299078A (zh) 一株适应全悬浮培养的猫肾细胞系f‑81 s及其应用
DE60037327D1 (de) Neues verfahren zur herstellung von virus-ähnlichen partikeln des menschen-papillomavirus mit verbesserten eigenschaften
CA2372709C (en) Vector for integration of heterologous sequences into poxviral genomes
Ijaz et al. Establishment of an in vitro regeneration system for genetic transformation of selected sugarcane genotypes
CN116286685A (zh) 一种基于CRISPR-Cas9技术的表达H9N2禽流感病毒XZ491毒株HA蛋白的重组血清4型禽腺病毒及其制备方法
CN1723285A (zh) 重组的mva及其产生方法
CN104087549B (zh) 高产杆状病毒的昆虫细胞系及其应用
Bradley et al. Transformation of African green monkey kidney cells with the RF strain of human papovarivus BKVB
CN111676198A (zh) 快速构建鸭坦布苏病毒反向遗传株的方法
JP2019511208A5 (enExample)
JP2005521423A5 (enExample)
Křižan et al. The effect of media composition on multiplication of grape rootstocks in vitro
JP2019511208A (ja) ウイルスを作製する方法
JP2003500059A5 (enExample)
CN111642395A (zh) 一种番茄抗病毒突变体的筛选方法
JP2006509526A (ja) トリ胚性幹細胞上におけるａｌｖａｃの産生